Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124156) titled 'Evaluation of the Efficacy and Safety of Recombinant Human Brain Natriuretic Peptide in Real-World Treatment of Sepsis Complicated with Cardiac Dysfunction' on May 8.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The Second Affiliated Hospital of Guangxi Medical University
Condition:
sepsis with concomitant cardiac dysfunction
Recruitment Status: Recruiting
Phase: 4
Date of First Enrollment: 2026-05-08
Target Sample Size: recombinant human brain natriuretic peptide group:50;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj...